Growth Based on Innovative and Appealing Products
Typically R&D investments are justified only to products that are 1) in demand (or will attract demand when launched to the market place), and 2) have more value for customers than combined production and selling costs. The same applies for services as well.
If the said product or service is also 3) scarce, due to e.g. IPRs (patenting) or needed very demanding knowhow, this product has reached so called Sweet Spot in the market place. A Sweet Spot is extremely appealing place because in that location it is very difficult to fail with your product or service.
In real life Sweet Spots are very rare. They exist only in certain exceptional situations. Nevertheless everybody bringing new products or services to the market place should try to aim at Sweet Spot, i.e. towards 1) sufficient demand, 2) value creation, and simultaneous 3) scarcity or limited competition.
Replicon Group helps its clients in integrating their “Sweet Spot Seeking” and related financial needs by helping to create viable financing strategy and also in raising financing. Our latest client was contract research organization (CRO) that provides services to pharmaceutical industry.
For further information on Replicon Group and its services, please contact:
Petteri Hirvonen, CEO
Replicon Group, +358 50 552 96 33 (direct)
This email address is being protected from spambots. You need JavaScript enabled to view it.
About Replicon Corporate Finance Ltd.
Replicon Corporate Finance Ltd. is an independent business development and corporate finance advisory house for growth companies and investors.
Replicon provides strategic and financial solutions that facilitate business activities, efficiency, and increase profitability of corporations and other organizations. Our core competence is in the corporate solutions that facilitate and govern growth of businesses based on innovation. Replicon Group’s special focus areas are Life Science and Cleantech sectors. Main shareholders in Replicon Group are its key management.
Ajakohtaista (embedded) UK
-
12-04-2017 All Resources in Replicon Health Ltd.
-
31-03-2016 Innovative Expansion and Financing Strategy
-
04-08-2015 Service Offering: “Acid tests” for Life Science Sector Investment Strategies and Investments
-
03-03-2015 Growth Based on Innovative and Appealing Products
-
01-04-2014 Replicon Gains Accreditation for Two Useful Client Programs
-
07-10-2013 Replicon Evaluates Production Methods for Unique Food Supplement
-
06-03-2013 Replicon Initiates Industrial Licensing Project
-
01-03-2013 Learning Points from Nalmefene / Selincro
-
25-10-2012 Comparing Economics of Wind Power Alternatives
-
13-08-2012 OS/G Advertising and Marketing Agengy Ezpa Merge
-
09-05-2012 Current Investment Opportunities for Investors and Financiers
-
20-02-2012 - Replicon Compiles Business Strategy and Financing Plan for 6 M€ Wellness Concept
-
31-08-2011 - Replicon Valuation Analyses Enhances M&A